How do the innate and adaptive immune systems differ in their cancer defense roles?

The innate immune system acts as a first alarm, consisting of cells like dendritic cells and macrophages that identify general patterns of foreign invaders or damage. The adaptive immune system, comprising T-cells and B-cells, is responsible for finely tuned responses. T-cells coordinate specific cell-mediated attacks, while B-cells produce antibodies that can target cancer cells, offering precision and memory against specific threats.

How does aging affect cancer risk and the development of mutations?

Cancer risk generally increases with age because cancer is an evolutionary process where cells accumulate mutations over time. With more time, cells divide more often, increasing the likelihood of DNA damage and mutations that can transform healthy cells into cancerous ones. This cumulative process is a major factor in why most cancers are diseases of later life.

What are the common environmental factors that increase cancer risk?

Significant environmental factors increasing cancer risk include smoking, excessive UV light exposure (for melanoma), and exposure to environmental toxins such as pesticides and certain industrial chemicals. While some lifestyle factors like charred meats may contribute to risk, the primary culprits with strong causative data remain smoking and high UV exposure.

How are modern immunotherapy drugs, like checkpoint inhibitors, different from traditional chemotherapy?

Traditional chemotherapy involves administering toxins to the body to kill cancer cells, often with severe side effects to healthy cells. Immunotherapy drugs, such as checkpoint inhibitors, work by 'unleashing' the body's own T-cells, which may be present but suppressed. By removing these 'brakes' on the immune system, T-cells become more active and effective in targeting and eliminating cancer cells with potentially fewer systemic side effects.

What is CRISPR and how does it allow for precise gene editing in cancer treatment?

CRISPR-Cas9 is a revolutionary gene-editing tool derived from a bacterial immune system that can precisely cut and paste DNA sequences. This allows scientists to not only remove genes that might impede T-cells but also introduce new genes, like those for CARs or resilience factors, to make T-cells more effective and durable against cancer. Its precision allows for targeted modifications to program specific cellular behaviors.

How is CRISPR delivered into target cells like T-cells for therapeutic purposes?

Initially, delivery was achieved by harvesting T-cells, exposing them to CRISPR components (protein and RNA) via electroporation (small electrical current to open cell pores), and then reinfusing them. More recent advancements include using engineered viruses with specific tropisms (cell-targeting abilities) and lipid nanoparticles (LNPs), which can be injected directly into the body and carry genetic material to specific cell types, such as T-cells or liver cells.

What are some ethical concerns surrounding CRISPR technology, particularly in human embryos?

Key ethical concerns include the potential for 'designer babies' through germline editing, which involves making heritable changes to embryos that would pass to future generations. This raises worries about creating false axes of perfection, influencing human diversity, and the long-term, unpredictable consequences of altering the human genome, moving beyond disease prevention to enhancement without full understanding of the implications.

Can gene-edited T-cells be used to treat autoimmune diseases?

Yes, the same CAR T-cell technology used for B-cell leukemias is now being explored to treat autoimmune diseases like lupus, rheumatoid arthritis, childhood diabetes, and multiple sclerosis. By engineering T-cells to specifically eliminate B-cells that contribute to autoimmune pathology, early trials are showing promising results in reducing autoimmune responses and restoring balance to the immune system.

What is the future outlook for gene editing and immunotherapy in medicine?

The future of gene editing and immunotherapy is rapidly accelerating. It involves high-throughput screening to understand how every gene contributes to cell behavior, creating a 'recipe book' for engineering immune cells. Technologies like induced pluripotent stem cells (iPSCs) are also being explored to create limitless supplies of T-cells, paving the way for programmable cells that can regenerate tissues or precisely target diseases without invasive procedures.

Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson

Andrew Huberman

Science & Technology4 min read148 min video

Mar 9, 2026|25,358 views|925|88

andrew huberman huberman lab podcast huberman podcast dr. andrew huberman neuroscience huberman lab andrew huberman podcast the huberman lab podcast science podcast

Save to Pod

Key Moments

TL;DR

CRISPR and CAR-T cells offer new ways to fight cancer by reprogramming the immune system.

Key Insights

The immune system, with its innate and adaptive arms, plays a crucial role in recognizing and eliminating threats like cancer cells.

CAR-T cell therapy genetically engineers a patient's T-cells to target and destroy cancer cells with high precision.

CRISPR technology allows for precise editing of DNA, enabling scientists to reprogram cells for therapeutic purposes, including cancer treatment.

Cancer arises from accumulated genetic mutations that lead to uncontrolled cell division and potential metastasis.

While conventional treatments like chemotherapy exist, immunotherapy and gene editing represent a paradigm shift in cancer treatment.

Ethical considerations surrounding germline gene editing and the development of 'designer babies' are significant concerns.

UNDERSTANDING THE IMMUNE SYSTEM'S ROLE IN FIGHTING CANCER

Our immune system is a complex network of cells, including innate and adaptive components like T-cells and B-cells, designed to defend against foreign invaders and abnormal cells. The adaptive immune system, particularly T-cells, plays a crucial role in recognizing and eliminating cancer cells. Through a complex process involving receptor generation and selection in the thymus, T-cells are educated to distinguish self from non-self. When functioning correctly, they can identify and attack cancerous cells, though cancer often develops mechanisms to evade the immune system.

CAR-T CELL THERAPY: PROGRAMMING IMMUNITY AGAINST CANCER

Chimeric Antigen Receptor (CAR) T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered in a lab to express synthetic receptors. These CARs are designed to specifically recognize and bind to proteins on the surface of cancer cells. Once re-introduced into the patient, these modified T-cells act as 'guided missiles,' actively searching for and destroying cancer cells. This therapy has shown remarkable success, particularly in treating certain leukemias and lymphomas.

CRISPR-CAS9: PRECISION GENE EDITING FOR THERAPEUTIC POTENTIAL

CRISPR-Cas9 technology has revolutionized our ability to precisely edit DNA, akin to editing the 'source code' of cells. Originally discovered as a bacterial defense mechanism against viruses, CRISPR can be programmed to target specific DNA sequences, enabling scientists to cut, remove, or insert genes. This precision allows for the reprogramming of various cell types, including T-cells, to enhance their anti-cancer activity or correct genetic defects. The development of CRISPR has moved from basic research to clinical trials, offering hope for treating a wide range of diseases.

DECODING CANCER: FROM GENETIC MUTATIONS TO EVOLUTIONARY PROCESSES

Cancer is fundamentally a genetic disease characterized by the accumulation of mutations in a cell's DNA. These mutations disrupt normal cell regulation, leading to uncontrolled proliferation, loss of normal function, and the potential for metastasis. This process is evolutionary, where cancer cells acquire new genetic advantages to survive and grow, often at the expense of the host body. Factors like environmental mutagens (e.g., smoking, UV radiation) and inherited predispositions (e.g., BRCA mutations) can accelerate the accumulation of these critical mutations.

ADVANCEMENTS IN DELIVERY MECHANISMS FOR GENE EDITING AND THERAPY

Delivering genetic material like CRISPR or therapeutic genes into target cells is a critical challenge. While lentiviruses have been used effectively, newer methods are emerging. Electroporation, which uses electrical pulses to create temporary pores in cell membranes, is a key technique for in-vitro cell modification. Beyond this, researchers are exploring lipid nanoparticles (LNPs), similar to those used in mRNA vaccines, and engineered viruses with specific tropisms to deliver genetic payloads directly into cells within the body, potentially enabling less invasive treatments.

ETHICAL CONSIDERATIONS AND THE FUTURE OF GENE EDITING

The power of gene editing, particularly CRISPR, raises significant ethical questions, especially concerning germline editing, which affects future generations. The case of human embryo editing for HIV resistance highlighted the global concern and the need for stringent ethical guidelines. While somatic cell editing for treating diseases is widely accepted, altering the germline brings risks of unintended consequences, loss of genetic diversity, and the potential pursuit of 'enhancements' rather than disease treatment. These discussions are crucial as the technology advances.

EMERGING THERAPIES AND THE INTERSECTION OF BIOLOGY AND TECHNOLOGY

The convergence of understanding cellular biology, immune function, and advanced technologies like CRISPR and AI is accelerating medical breakthroughs. Future therapies may involve precisely engineered immune cells, targeted drug delivery using novel nanoparticles and antibodies, and potentially AI-designed proteins. The ongoing research in regenerative medicine, using induced pluripotent stem cells (iPSCs), further expands the possibilities for cell-based therapies and organ regeneration, promising a new era of personalized and effective treatments for a multitude of diseases.

Mentioned in This Episode

●Supplements

●Tools & Products

●Books

●People Referenced

Common Questions

CAR T-cells are T-cells that have been genetically engineered in a lab to express artificial receptors (Chimeric Antigen Receptors) on their surface. These receptors program the T-cells to identify and destroy specific cancer cells without targeting healthy cells, effectively turning the immune system into a cancer-fighting tool. This approach has shown remarkable success in certain leukemias and lymphomas.

Topics

Gene Editing T-cells B-cells Autoimmunity DNA Mutations Molecular Biology Lipid Nanoparticles Vaccines Medical Ethics Oncology

Mentioned in this video

personAlex Marson

Medical doctor and scientist at UCSF developing new ways to reprogram the immune system to cure cancers using gene editing and other technologies.

toolDendritic cells

Cells of the innate immune system that act as primary alarm systems, sensing patters of foreign invaders or damage.

toolMacrophages

Cells of the innate immune system that act as primary alarm systems, seeking out and engulfing foreign particles.

personSager Bapat

A postdoc in Dr. Marson's lab who studied the effect of metabolic health on T-cells, showing qualitative differences in immune responses with high-fat diets in mice.

bookThe Emperor of All Maladies

A biography of cancer as a disease, highly recommended for understanding its long history and evolution.

personMichael Sandel

Harvard philosopher and author of 'The Case Against Perfection,' a book that explores the ethical implications of genetic engineering and the pursuit of perfection.

toolLymphocytes (B cells and T-cells)

Major white blood cell types of the adaptive immune system. T-cells coordinate immune responses, while B-cells produce antibodies.

toolThymus

An organ crucial for the 'education' of T-cells during childhood, where T-cells are selected to recognize foreign targets and avoid self-targets.

toolBetterHelp

An online platform offering professional therapy with licensed therapists.

personShauna Swan

Mentioned as an expert who discussed cancer and endocrine disruptor risks from pesticides, highlighting their impact in rural areas.

personJimmy Carter

Former US President who was cured of metastatic melanoma (skin cancer that spread to his brain) using checkpoint inhibitors.

personEmily Whitehead

The first pediatric patient treated with CAR T-cells for leukemia in 2012; she was cured and is now a premed student.

toolLentiviruses

Modified viruses, similar to HIV, used as shuttles to deliver specific genes, like CAR DNA, into T-cells for genetic modification.

personEmmanuelle Charpentier

Nobel Prize laureate (with Jennifer Doudna) for the development of CRISPR-Cas9.

toolCD19

A protein target found on many B-cell leukemias and lymphomas, and also on healthy B-cells, making it an effective target for CAR T-cell therapy.

personWatson and Crick

Scientists known for their discovery of the double helix structure of DNA.

toolCas9 protein

A protein 'scissor' enzyme in the CRISPR system that cuts DNA at specific sequences, guided by an RNA molecule.

personDavid Liu

Researcher at Harvard who developed CRISPR base editors, which introduce predictable nucleotide changes without double-stranded breaks.

supplementElement (LMNT)

An electrolyte drink with sodium, magnesium, and potassium in correct ratios, without sugar, to support hydration.

personKatherine Schumann

First postdoc in Dr. Marson's lab who optimized the electroporation protocol for delivering CRISPR protein and RNA into T-cells.

personTheo Roth

A graduate student in Dr. Marson's lab who extended the electroporation method to introduce large pieces of DNA (hundreds to thousands of nucleotides) using CRISPR.

toolArsenal Biosciences

A company co-founded based on technology from Dr. Marson's lab, now in clinical trials for solid tumors (e.g., prostate cancer) using CRISPR-engineered CAR T-cells with enhanced resilience.

toolGladstone UCSF Institute of Genomic Immunology

An institute run by Dr. Marson that is starting philanthropically funded CRISPR trials for multiple myeloma.

toolLipid Nanoparticles (LNPs)

Fatty bubbles used to deliver genetic material, such as mRNA in vaccines (e.g., COVID vaccines) or CRISPR components, into cells; can be engineered for cell-specific targeting.

toolSaporin toxin

A highly potent toxin that can be conjugated to antibodies to selectively kill cells, used experimentally in immunotoxins.

toolAmgen

A large pharmaceutical company that is a leader in bispecific T-cell engagers ('bites'); uses AI to design synthetic proteins for cancer targeting.

toolCCR5 gene

A gene that, if deleted, can confer resistance to HIV; was the target of unauthorized CRISPR edits in human embryos by a Chinese scientist.

personJoe Chen

Scientist at Princeton who conducted early work on enhancing memory in mice by manipulating genes related to the NMDA receptor.

personShinya Yamanaka

Nobel Prize laureate who discovered that mature cells can be reprogrammed to become induced pluripotent stem cells (iPSCs) using specific transcription factors.